Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Feb
12
Today In Oncology
PSMA PET/CT-Guided Radiotherapy After Prostatectomy
Rural Populations Face Greater Barriers as Nonmedical Costs Hinder Cancer Clinical Trial Access
FDA Approves Pembrolizumab With Paclitaxel for Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
A New Risk Model for Esophagectomy Draws on the STS National Database
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo